Infant Bacterial Therapeutics Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de Infant Bacterial Therapeutics.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	73.2%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

Aug 02

Infant Bacterial Therapeutics AB (publ)'s (STO:IBT B) CEO Compensation Is Looking A Bit Stretched At The Moment

May 02

Infant Bacterial Therapeutics (STO:IBT B) Is In A Good Position To Deliver On Growth Plans

Apr 03

Here's Why We're Not Too Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Situation

Sep 16

We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

May 11

We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate

Sep 23

We're Hopeful That Infant Bacterial Therapeutics (STO:IBT B) Will Use Its Cash Wisely

Apr 07

We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

Dec 15

We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

Aug 25

We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate

May 06

Anthon Jahreskog Just Bought A Sprinkling of Shares In Infant Bacterial Therapeutics AB (publ) (STO:IBT B)

Feb 07

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Infant Bacterial Therapeutics no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

OM:IBT B - Estimaciones futuras de los analistas y datos financieros pasados (SEK Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
9/30/2024	0	-144	-134	-134	N/A
6/30/2024	0	-142	-121	-121	N/A
3/31/2024	0	-128	-97	-97	N/A
12/31/2023	0	-123	-101	-101	N/A
9/30/2023	0	-122	-95	-95	N/A
6/30/2023	0	-99	-88	-88	N/A
3/31/2023	0	-69	-103	-103	N/A
12/31/2022	0	-65	-86	-86	N/A
9/30/2022	0	-42	-73	-73	N/A
6/30/2022	0	-34	-76	-76	N/A
3/31/2022	N/A	-65	-57	-57	N/A
12/31/2021	N/A	-45	-56	-56	N/A
9/30/2021	N/A	-55	-76	-76	N/A
6/30/2021	N/A	-74	-57	-57	N/A
3/31/2021	N/A	-73	-60	-60	N/A
12/31/2020	N/A	-72	-58	-58	N/A
9/30/2020	N/A	-73	-37	-37	N/A
6/30/2020	N/A	-65	-65	-65	N/A
3/31/2020	N/A	-44	-54	-54	N/A
12/31/2019	N/A	-46	-51	-51	N/A
9/30/2019	N/A	-43	-67	-67	N/A
6/30/2019	N/A	-40	-42	-42	N/A
3/31/2019	N/A	-32	-45	-45	N/A
12/31/2018	N/A	-41	-47	-47	N/A
9/30/2018	N/A	-26	-30	-30	N/A
6/30/2018	N/A	-22	N/A	-30	N/A
3/31/2018	0	-37	N/A	-34	N/A
12/31/2017	0	-36	N/A	-35	N/A
9/30/2017	0	-41	N/A	-42	N/A
6/30/2017	0	-44	N/A	-41	N/A
3/31/2017	0	-42	N/A	-42	N/A
12/31/2016	0	-38	N/A	-40	N/A
9/30/2016	0	-19	N/A	-34	N/A
6/30/2016	N/A	-7	N/A	-33	N/A
3/31/2016	N/A	0	N/A	-23	N/A
12/31/2015	N/A	0	N/A	-17	N/A
12/31/2014	N/A	0	N/A	N/A	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de IBT B es superior a la tasa de ahorro (1.2%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de IBT B crezcan más rápidamente que el mercado Swedish

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de IBT B crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de IBT B crezcan más rápidamente que el mercado de Swedish.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de IBT B crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de IBT B se prevé que sea elevada dentro de 3 años.

Infant Bacterial Therapeutics Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Infant Bacterial Therapeutics AB (publ) to Report Q3, 2025 Results on Nov 13, 2025

Infant Bacterial Therapeutics AB (Publ) Announces the Appointment of the Nomination Committee for the Annual General Meeting 2025

Independent Director recently bought kr350k worth of stock

New minor risk - Market cap size

Infant Bacterial Therapeutics Announces Results of Phase III Study Shows No Significant Effects on the Primary Endpoints

New minor risk - Share price stability

We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

Independent Director recently bought kr222k worth of stock

Infant Bacterial Therapeutics AB (publ)'s (STO:IBT B) CEO Compensation Is Looking A Bit Stretched At The Moment

Infant Bacterial Therapeutics (STO:IBT B) Is In A Good Position To Deliver On Growth Plans

Infant Bacterial Therapeutics AB (publ) to Report Nine Months, 2024 Results on Nov 14, 2024

New minor risk - Market cap size

Independent Director recently bought kr94k worth of stock

Independent Director recently bought kr90k worth of stock

Infant Bacterial Therapeutics AB (Publ) Announces the Appointment of the Nomination Committee for the Annual General Meeting 2024

Here's Why We're Not Too Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Situation

Infant Bacterial Therapeutics AB (publ) to Report Fiscal Year 2023 Results on Feb 08, 2024

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

Independent Director recently bought kr86k worth of stock

We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

Infant Bacterial Therapeutics AB (publ) Publishes Clinical Findings in British Journal of Gastroenterology

Infant Bacterial Therapeutics AB Secures Platform for Pharma Grade Probiotic to Prevent Antibiotic Resistant Hospital Acquired Infections

Insufficient new directors

Infant Bacterial Therapeutics AB (publ) Announces Nomination Committee Appointments

FDA Approves Infant Bacterial Therapeutics' Request for a New Orphan Drug Designation

We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate

Infant Bacterial Therapeutics AB (publ) to Report Q2, 2023 Results on Aug 25, 2023

Infant Bacterial Therapeutics AB (publ) Appoints Maria Ekdahl as Chief Financial Officer, Effective September 19, 2022

Insufficient new directors

Infant Bacterial Therapeutics AB (Publ) Announces Retirement of Michael Owens as CFO

We're Hopeful That Infant Bacterial Therapeutics (STO:IBT B) Will Use Its Cash Wisely

Independent Director recently bought kr59k worth of stock

Infant Bacterial Therapeutics Announces the Connection Study Continues After Pre-Scheduled Data Monitoring Committee Review

Infant Bacterial Therapeutics AB Announces New Patent Protection Granted in Australia

Infant Bacterial Therapeutics Announces New Patent Protection Approvals in Brazil and in Hong Kong

We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

Infant Bacterial Therapeutics AB (publ) Announces After Safety Review the Connection Study Is Now Again Open to Recruit the Smallest Infants

Infant Bacterial Therapeutics Announces the Mexican Patent Office Grants New Patent

Infant Bacterial Therapeutics AB (Publ) Announces Recruitment of the Smallest Infants in the Connection Study Paused

We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

Interim Chief Financial Officer Michael Owens has left the company

Independent Director recently bought kr113k worth of stock

Independent Director recently bought kr113k worth of stock

Director recently bought kr382k worth of stock

We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate

Chief Operating Officer recently bought kr350k worth of stock

Infant Bacterial Therapeutics Announces That the Recruitment to the First Stage of the Phase III Connection Study Is Completed - an Update About the Clinical Development of IBP-9414

Infant Bacterial Therapeutics Announces Grant of New Patent in Japan

Anthon Jahreskog Just Bought A Sprinkling of Shares In Infant Bacterial Therapeutics AB (publ) (STO:IBT B)

Insider recently bought kr118k worth of stock

New 90-day low: kr106

New 90-day low: kr123

New 90-day low: kr131

Infant Bacterial Therapeutics AB (publ) to Report Q1, 2021 Results on May 04, 2021

New 90-day high - kr119

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento